Targets › PARP2
37 programs from 31 companies in 346 trials: 161 Phase 2, 132 Phase 1, 46 Phase 3, 7 Phase 4; Oncology, Other, Genitourinary; next expected readout Nov 2026.
Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair. Mediates glutamate, aspartate or serine ADP-ribosylation of proteins: the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average…. (UniProt, Q9UGN5)
Open in Phaseline: the race on PARP2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Olaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 4 | Metastatic Castration-resistant Prostate Cancer; Advanced Ovarian Cancer; Platinum Sensitive; Endometrial Neoplasms … | Nov 2026 |
| M.D. Anderson Cancer Center | [18F]-4FN PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2, CHRNB2, CHRNA4, Tubulin, OPRM1, CD274 | Phase 4 | Lymphoma; Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm … | Dec 2026 |
| GSK | Niraparib Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 3 | Neoplasms, Breast; Ovarian Neoplasms; Neoplasms | Dec 2026 |
| Guangdong Provincial People's Hospital | Fuzuloparib PARP inhibitor | PARP1, PARP2 | Phase 3 | Triple-negative Breast Cancer | Dec 2026 |
| Jiangsu HengRui Medicine | Fuzuloparib PARP inhibitor | PARP1, PARP2 | Phase 3 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Dec 2026 |
| Johnson & Johnson (Janssen) | Niraparib Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 3 | Prostatic Neoplasms; Castration-Resistant Prostatic Cancer; Prostatic Neoplasms, Castration-Resistant; Ovarian Cancer … | Dec 2026 |
| Pfizer | Talazoparib Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 3 | Advanced Malignancies; mCRPC; Prostate Cancer; Urothelial Carcinoma … | Dec 2026 |
| BeiGene | Pamiparib (BGB-290) Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor | PARP1, PARP2 | Phase 3 | Ovarian Cancer; Locally Advanced Prostate Cancer; Head and Neck Cancer; Glioblastoma | Jan 2027 |
| Alliance for Clinical Trials in Oncology | Rucaparib camsylate PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 3 | Castration-Resistant Prostate Carcinoma | Mar 2027 |
| Fudan University | Fluzoparib PARP inhibitor | PARP1, PARP2 | Phase 3 | Neoadjuvant Therapy; Breast Cancer; Breast Cancer Metastatic | Apr 2027 |
| The Netherlands Cancer Institute | ddAC-CP-Olaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP2, PARP3 | Phase 3 | Breast Cancer; Cancer; Ovarian Cancer | May 2027 |
| Merck & Co. (MSD) | Olaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 3 | Lung Neoplasms; Small Cell Lung Cancer; Solid Tumors; Advanced Solid Neoplasms … | May 2027 |
| AstraZeneca | Saruparib PARP inhibitor | PARP1, PARP2 | Phase 3 | Metastatic Castration-Sensitive Prostate Cancer; Advanced Breast Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Prostate Cancer … | Sep 2027 |
| Tesaro | Niraparib Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 3 | Ovarian Neoplasms | Apr 2029 |
| Tongji Hospital | Fluzoparib PARP inhibitor | PARP1, PARP2 | Phase 3 | Ovarian Cancer | May 2030 |
| pharmaand | Rucaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 3 | Epithelial Ovarian Cancer; Leiomyosarcoma; Peritoneal Cancer; Adenocarcinoma of the Oesophagus … | Dec 2030 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Fluorizoparib PARP1/2 inhibitor | PARP1, PARP2 | Phase 3 | Metastatic Breast Cancer | Mar 2031 |
| Impact Therapeutics | IMP4297 PARP inhibitor | PARP1, PARP2 | Phase 3 | Ovarian Cancer | – |
| National Cancer Institute (NCI) | Veliparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 2 | Acute Myeloid Leukemia; Glioblastoma; Locally Advanced Pancreatic Adenocarcinoma; Recurrent Lung Small Cell Carcinoma … | Nov 2026 |
| Ruijin Hospital | Fluzoparib PARP inhibitor | PARP1, PARP2 | Phase 2 | Sarcoma | Dec 2026 |
| M.D. Anderson Cancer Center | Talazoparib Tosylate Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 2 | Prostate Cancer; Advanced Malignant Neoplasm; Malignant Female Reproductive System Neoplasm; Advanced Malignant Solid Neoplasm | Dec 2026 |
| Allarity Therapeutics | 2X-121 Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor; Tankyrase 1/2 inhibitor | PARP1, PARP2, TNKS2, TNKS | Phase 2 | Advanced Ovarian Cancer | Mar 2027 |
| Sun Yat-sen University | Temozolomide PARP inhibitor | PARP1, PARP2 | Phase 2 | Ewing Sarcoma | Apr 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Fluzoparib Poly (ADP-ribose) polymerase (PARP) inhibitor | PARP1, PARP2 | Phase 2 | Platinum-sensitive | Nov 2027 |
| Fujian Cancer Hospital | Fuzuloparib PARP inhibitor | PARP1, PARP2 | Phase 2 | Ovarian Neoplasms | Dec 2027 |
| AstraZeneca | AZD5305 PARP inhibitor | PARP1, PARP2 | Phase 1 | Prostate Cancer; Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer; Ovarian Cancer; Breast Cancer … | Nov 2026 |
| Jun Guo | Fluzoparib PARP inhibitor | PARP1, PARP2 | Phase 1 | Melanoma | Dec 2026 |
| Daewoong Pharmaceutical | Olaparib (DWZ2501) PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 1 | Cancer | Mar 2027 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Niraparib Tosylate Monohydrate Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 1 | Ovarian Cancer | Mar 2027 |
| Memorial Sloan Kettering Cancer Center | PARPi-FL PARP inhibitor-based fluorescent imaging dye | PARP1, PARP2 | Phase 1 | Oral Squamous Cell Carcinoma (OSCC) | Jul 2027 |
| Memorial Sloan Kettering Cancer Center | [18F]-PARPi PARP inhibitor-based PET imaging agent | PARP1, PARP2 | Phase 1 | Head and Neck Cancer | Aug 2027 |
| AstraZeneca | Palacaparib (AZD9574) PARP inhibitor | PARP1, PARP2 | Phase 1 | Breast Cancer; Advanced Solid Malignancies; Metastatic Prostate Cancer | Sep 2027 |
| Acerand Therapeutics (Shanghai) | ACE-86225106 PARP inhibitor | PARP1, PARP2 | Phase 1 | Solid Tumor, Adult | Dec 2028 |
| VA Office of Research and Development | Stenoparib/Temozolomide PARP inhibitor plus alkylating agent | PARP1, PARP2 | Phase 1 | Relapsed Small Cell Lung Cancer | Dec 2029 |
| AstraZeneca | AZD4956 PARP inhibitor | PARP1, PARP2 | Phase 1 | Solid Tumours | Mar 2030 |
| Xing Xie | Fuzuloparib PARP inhibitor | PARP1, PARP2 | Phase 1 | Efficacy and Safety | – |
| Boryung Pharmaceutical | Olaparib (BR2022) PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 1 | Ovarian Cancer | – |
Ovarian Cancer (25) Breast Cancer (17) Prostate Cancer (12) Advanced Malignant Solid Neoplasm (10) Acute Myeloid Leukemia (9) Glioblastoma (5) Metastatic Prostate Cancer (5) Metastatic Breast Cancer (4) Metastatic Castration-resistant Prostate Cancer (4) Endometrial Cancer (4) Advanced Breast Cancer (4) Solid Tumor (4)
small molecule (26), mixed (8), antibody (3)
AstraZeneca (5) M.D. Anderson Cancer Center (2) Memorial Sloan Kettering Cancer Center (2) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) Merck & Co. (MSD) (1) Tianjin Medical University Cancer Institute and Hospital (1) National Cancer Institute (NCI) (1) Pfizer (1) Johnson & Johnson (Janssen) (1) Tongji Hospital (1) VA Office of Research and Development (1) Jun Guo (1) Ruijin Hospital (1) GSK (1) Guangdong Provincial People's Hospital (1) Fujian Cancer Hospital (1) BeiGene (1) Impact Therapeutics (1) pharmaand (1) The Netherlands Cancer Institute (1)
PARP1 (37) PARP3 (9) TNKS2 (1) TNKS (1) CHRNB2 (1) CHRNA4 (1) Tubulin (1) OPRM1 (1) CD274 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.